Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott (NYSE: ABT) today announced the first global procedures have been conducted using the company’s new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib). Over 30 patients were recently treated…